EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG

BACKGROUND: We previously discovered high expression of the disialoganglioside GD2 on H3K27M+ gliomas and demonstrated preclinical efficacy of intravenous (IV) GD2-targeted chimeric antigen receptor (CAR) T-cells in preclinical models of H3K27M-mutated diffuse intrinsic pontine glioma (DIPG) and dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Majzner, Robbie, Ramakrishna, Sneha, Mochizuki, Aaron, Patel, Shabnum, Chinnasamy, Harshini, Yeom, Kristen, Schultz, Liora, Richards, Rebecca, Campen, Cynthia, Reschke, Agnes, Mahdi, Jasia, Toland, Angus Martin Shaw, Baggott, Christina, Mavroukakis, Sharon, Egeler, Emily, Moon, Jennifer, Landrum, Kayla, Erickson, Courtney, Rasmussen, Lindsay, Barsan, Valentin, Tamaresis, John, Marcy, Anne, Kunicki, Michael, Fujimoto, Michelle, Ehlinger, Zach, Kurra, Sreevidya, Cornell, Timothy, Partap, Sonia, Fisher, Paul, Grant, Gerald, Vogel, Hannes, Sahaf, Bita, Davis, Kara, Feldman, Steven, Mackall, Crystal, Monje, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Translational/Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168142/
http://dx.doi.org/10.1093/neuonc/noab090.200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168142/
http://dx.doi.org/10.1093/neuonc/noab090.200

Ejemplares similares